-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised blinatumomab,
dasatinib, imatinib, inotuzumab and ponatinib for patients with acute
lymphoblastic leukaemia (ALL).

ALL and listing dates

ALL is a type of blood cancer.

Listing dates:

-   dasatinib - 1 December 2007
-   imatinib - 1 December 2007
-   ponatinib – 1 November 2015
-   blinatumomab - 1 May 2017
-   inotuzumab ozogamicin - 1 May 2019

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
items and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
